alprazolam has been researched along with trazodone in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Halaris, A; Saran, A | 1 |
| Ostrow, D | 1 |
| Brown, TM; Evans, DL; Golden, RN; Miller, H | 1 |
| Aiken, B; Charney, DS; Goodman, WK; Heninger, GR; Kinch, M; Quadrino, LM; Rifkin, B; Woods, SW | 1 |
| Golden, RN; Potter, WZ; Rudorfer, MV | 1 |
| Haida, M; Itoh, K | 1 |
| Cotreau, MM; Greenblatt, DJ; Tran, TH; von Moltke, LL | 1 |
| Koval'chuk, VV | 1 |
3 review(s) available for alprazolam and trazodone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The new antidepressants.
Topics: Alprazolam; Amoxapine; Antidepressive Agents; Fluoxetine; Maprotiline; Nomifensine; Seizures; Trazodone | 1988 |
Second-generation antidepressants.
Topics: Alprazolam; Amoxapine; Antidepressive Agents; Benzodiazepines; Bupropion; Citalopram; Clinical Trials as Topic; Dopamine; Double-Blind Method; Humans; Maprotiline; Nomifensine; Norepinephrine; Propiophenones; Propylamines; Seizures; Serotonin; Trazodone; Zimeldine | 1984 |
4 trial(s) available for alprazolam and trazodone
| Article | Year |
|---|---|
The new generation antidepressants: promising innovations or disappointments?
Topics: Alprazolam; Antidepressive Agents; Benzodiazepines; Bupropion; Citalopram; Clinical Trials as Topic; Depressive Disorder; Dopamine; Drug Evaluation; Fluoxetine; Humans; Maprotiline; Nomifensine; Norepinephrine; Propiophenones; Propylamines; Receptors, Neurotransmitter; Serotonin; Trazodone; Zimeldine | 1985 |
Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Fear; Humans; Imipramine; Panic; Patient Dropouts; Psychiatric Status Rating Scales; Time Factors; Trazodone | 1986 |
Second-generation antidepressants.
Topics: Alprazolam; Amoxapine; Antidepressive Agents; Benzodiazepines; Bupropion; Citalopram; Clinical Trials as Topic; Dopamine; Double-Blind Method; Humans; Maprotiline; Nomifensine; Norepinephrine; Propiophenones; Propylamines; Seizures; Serotonin; Trazodone; Zimeldine | 1984 |
[Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors].
Topics: Adult; Alprazolam; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Brain Neoplasms; Depression; Doxepin; Emotions; Female; Humans; Male; Maprotiline; Middle Aged; Moclobemide; Mood Disorders; Neurosurgical Procedures; Nialamide; Sertraline; Thiazepines; Trazodone; Treatment Outcome | 2007 |
10 other study(ies) available for alprazolam and trazodone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Panic attack precipitated by fluoxetine.
Topics: Adult; Alprazolam; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Panic Disorder; Psychiatric Status Rating Scales; Trazodone | 1989 |
[Clinical effect of alprazolam and trazodone on bronchial asthmatics with anxiety disorder].
Topics: Adult; Aged; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Asthma; Female; Humans; Male; Middle Aged; Trazodone | 1997 |
Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region.
Topics: Adult; Alprazolam; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Humans; Male; Metabolic Clearance Rate; Mixed Function Oxygenases; Promoter Regions, Genetic; Trazodone | 2000 |